Press Releases

August 9, 2023
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model

June 6, 2023
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update

June 3, 2023
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

June 2, 2023
Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer

June 1, 2023
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica

May 1, 2023
Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO

April 27, 2023
Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors

October 4, 2022
Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response

September 20, 2022
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines

September 7, 2022
Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2

Investor Relations Contact

Heather DiVecchia
Elicio Therapeutics
Tel: (857) 209-0153
IR@elicio.com

Email Alerts Sign-Up